RSV vax beneficial, cost-effective in elderly with health conditions: Study
New Delhi, Sep 9 (IANS) Administering the respiratory syncytial virus (RSV) in older adults with underlying health conditions may be a cost-effective way to reduce disease, a modelling study showed on Monday. While RSV infections are known to cause major illness, especially in infants, the rate of infection increases with age. It can be dangerous
New Delhi, Sep 9 (IANS) Administering the respiratory syncytial virus (RSV) in older adults with underlying health conditions may be a cost-effective way to reduce disease, a modelling study showed on Monday.
While RSV infections are known to cause major illness, especially in infants, the rate of infection increases with age. It can be dangerous for older adults, especially those with certain medical conditions, and can cause serious complications like pneumonia, asthma, and chronic obstructive pulmonary disease (COPD).
There are now vaccines available to prevent disease caused by RSV in adults, and vaccination campaigns may reduce the incidence in older adults and associated health care costs, said the team of researchers led by the Public Health Agency of Canada.
In the paper published in the Canadian Medical Association Journal), the team created a model to assess the cost-effectiveness of vaccine programmes in various age groups with different medical risks.
They focused on adults aged 50 and older. They analysed a combination of age-only, medical risk–only and age-plus medical risk-based vaccination strategies. The strategies focused on adults were found to be more cost-effective
“We found that vaccination of older adults may be less costly and more effective than no vaccination and that vaccinating people aged 70 years and older with chronic medical conditions is likely to be cost-effective based on commonly used cost-effectiveness thresholds,” said Dr. Ashleigh Tuite, the Centre for Immunisation Programmes at the Public Health Agency.
RSV is likely to cause only mild symptoms similar to that of a common cold in the majority of people. However, for some at high risk, it can turn severe and even be life-threatening.
The US Centers for Disease Control and Prevention (CDC) recommends everyone ages 75 and older get an RSV vaccine.
The RSV vaccine is currently not an annual shot, meaning older adults do not need to get a dose every RSV season.
–IANS
rvt/
ସମ୍ବଲପୁରରେ ସି.ଏମ କିଷାନ ସହାୟତା ଯୋଜନାର ଶୁଭାରମ୍ଭ କଲେ ମୁଖ୍ୟମନ୍ତ୍ରୀ
Next Articleଶ୍ରୀମନ୍ଦିରରେ ଋଷି ପଞ୍ଚମୀ ନୀତି ସମ୍ପର୍ଣ୍ଣ
Related Articles
New AI tool to revolutionise personalised cancer treatment

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀNew AI tool to revolutionise personalised cancer treatment
New Delhi: An international team of scientists has developed an artificial intelligence (AI) tool that could revolutionise cancer treatment by mapping cellular diversity within tumours. The innovation tackles tumour heterogeneity in oncology, where varied cell populations cause treatment resistance and recurrence, Xinhua news agency reported. The AAnet AI tool, developed by the Sydney-based Garvan Institute
Covid-19 virus protein triggers immune attack on healthy cells: Study

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀCovid-19 virus protein triggers immune attack on healthy cells: Study
New Delhi: Amid a fresh wave of Covid-19, Israeli researchers have discovered that a protein from the SARS-CoV-2 virus can cause the immune system to attack healthy cells mistakenly. The study, published in the journal Cell Reports, sheds light on how severe Covid complications may occur and suggests new ways to prevent immune-driven damage from
Global AI collaboration revolutionises personalised cancer treatment

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀGlobal AI collaboration revolutionises personalised cancer treatment
New Delhi: An international team of scientists has unveiled an artificial intelligence (AI) technique that securely analyses global cancer samples, paving the way for more personalised and privacy-protected cancer treatments. This innovative approach promises to accelerate personalised cancer treatment by enabling clinicians to match therapies to individual patients better, Xinhua news agency reported. The study
